Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index.
Abstract
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists. The GLP-1 receptor agonists currently approved in the United States for the treatment of type 2 diabetes include exenatide (administered twice daily), liraglutide and lixisenatide (administered once daily), and the once-weekly agents exenatide extended-release, albiglutide, and dulaglutide. These agents have been shown to reduce A1C (by ∼0.8–1.6%), body weight (by ∼1–3 kg), blood pressure, and lipids. GLP-1 receptor agonists are associated with a low risk of hypoglycemia, and the most common adverse effects are gastrointestinal. Proper patient selection and education can assist in achieving positive treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The GI AE profile of semaglutide 2.4 mg in the STEP trials is consistent with previous observations with lower semaglutide doses and the established AE profile of GLP‐1RAs. 14 , 28 , 29”
From Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As higher incidences of GI AEs tend to be experienced with higher doses of GLP‐1RAs, gradual dose escalation and dose adjustment may help mitigate the impact of GI AEs in clinical practice. 29 , 30”
In the citing paper
“GLP-1-targeted therapies offer effective management of body weight and blood glucose levels, with underlying improvements to β-cell function and peripheral insulin sensitivity ( Zander et al., 2002 ; Hinnen, 2017 ).”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Hinnen, 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Similar positive cardiovascular results were reported recently for semaglutide, an investigational GLP-1 receptor agonist administered QW (33).”
ResultMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Two incretin hormones have been identified: glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) (4).”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“O R G The incretin system has become an important target in the treatment of type 2 diabetes in recent years (1).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“ings of the ELIXA outcomes study were neutral with respect to cardiovascular outcomes (31), whereas liraglutide demonstrated advantages versus placebo in the LEADER trial (32).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is reduced in people with type 2 diabetes (6).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Research works printed but not linked: 2
- Johnson, 2014, Integrated phase 3 immunogenicity results for albiglutide, Diabetes, 63, A427
- Milicevic, 2015, Low incidence of anti-drug antibody in type 2 diabetes patients treated with once-weekly dulaglutide, Diabetes, 64, A292
Cited by
Items 201–300 of 410
Yitayew, M. Y., Luginina, M., & Tabrizian, M. (2024) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300097 · Cited by 9
Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes
Blakely, K. K., & Weaver, K. (2020) · Nursing for Women s Health · doi:10.1016/j.nwh.2020.07.005 · Cited by 9
Phillips, J., Chen, J. H. C., Ooi, E. M. M., Prunster, J., & Lim, W. H. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.731574 · Cited by 11
de Gaetano, M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101699 · Cited by 9
Jung, Y.-H., Park, S. H., Lim, W. Y., Hong, J., Baik, J., Lee, H. J., Kwon, J.-Y., & Kim, E. (2025) · The Korean journal of pain · doi:10.3344/kjp.24419 · Cited by 9
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used to treat diabetes and obesity, and are known for their effectiveness and minimal side effects [18,19].”
Correia, A. S., Pereira, S., Morais, T., Martins, A. D., Monteiro, M. P., Alves, M. G., & Oliveira, P. F. (2022) · Biomedicines · doi:10.3390/biomedicines10102609 · Cited by 8
“GLP-1 is a gastrointestinal hormone that has been demonstrated to decrease food intake and promote weight loss in a dose-dependent manner, both in humans and animals [37,38].”
BackgroundPetrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
“…after its administration to patients with type 2 diabetes include: decreased glucagon concentrations, improved insulin sensitivity, decreased HbA1c levels, delayed gastric emptying, increased feelings of satiety, decreased free fatty acid concentrations and decreased body weight (Hinnen 2017).”
BackgroundAlenzi, S., Alzahrani, A., Aljaloud, A., Alanazi, K., & Alarfaj, S. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1395651 · Cited by 10
“Overall, the results from RCTs and real-world studies revealed that weekly semaglutide was associated with statistically signi fi cant and clinically relevant improvements in HbA1c and body weight in a wide range of adults with T2DM (11 – 15).”
BackgroundInfluentialSharma, S., Choudhary, M., Sharma, O., Injeti, E. R., & Mittal, A. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108185 · Cited by 8
Practical application of semaglutide: From evidence-based research to expert decisions
Салухов, В. В., Galstyan, G. R., Khalimov, Y. S., Бакулин, И. Г., Cherkashin, D. V., Shadrichev, F. E., & Sukhotskaia, N. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-185 · Cited by 8
Glucagon-like Peptide-1 Receptor Agonists
Collins, L., & Costello, R. A. (2019) · StatPearls · Cited by 64
Esteghamati, A., Zamanzadeh, M., Malek, M., Khaledi, M., MONAVVARI, A., Najafi, L., Banazadeh, Z., Malboosbaf, R., Aghili, R., Mahdikhah, S., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01462-w · Cited by 9
Anti-diabetics and the Prevention of Dementia: A Systematic Review
Slouha, E., Ibrahim, F., Rezazadah, A., Esposito, S., Clunes, L. A., & Kollias, T. F. (2023) · Cureus · doi:10.7759/cureus.49515 · Cited by 11
Franch‐Nadal, J., Mata‐Cases, M., Ortega, E., Real, J., Gratacòs, M., Vlacho, B., Vallés, J. A., & Mauricio, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091389 · Cited by 8
“, exenatide extended-release, dulaglutide, and albiglutide [not currently marketed or distributed]) [8,9].”
BackgroundSmall-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
Șeremet, O. C., Pușcașu, C., Andrei, C., Nițulescu, G., Zbârcea, C. E., & Olaru, O. T. (2025) · Medicina · doi:10.3390/medicina61111902 · Cited by 12
Regulation of therapeutic protein release in response to circadian biomarkers
Franko, N., Li, S., Galvan, S., Csorba, Z., Teixeira, A. P., Xie, M., & Fussenegger, M. (2025) · Nature Communications · doi:10.1038/s41467-025-64761-9 · Cited by 9
“The present system with GLP-1 as a therapeutic output may have translational potential for circadian rhythm-regulated once-daily therapy for obesity 47 or type-2 diabetes treatment 56 .”
Mirzaei, F., Khodadadi, I., Majdoub, N., Vafaei, S. A., Tayebinia, H., & Oshaghi, E. A. (2022) · The Open Medicinal Chemistry Journal · doi:10.2174/18741045-v16-e2212130 · Cited by 7
Glucagon-like peptide-1 analogues for overweight or obese adults
Madrid, E., Vargas, M. O., Contreras, C., Saldías, C., Liquitay, C. M. E., Victoria Novik, A., Muñoz, S., & Bracchiglione, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092 · Cited by 7
Klein, G., Petrone, M., Yang, Y., Hoang, T., Hazlett, S., Hansen, L. B., & Flor, A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01239-1 · Cited by 7
“However, progression to ESRD has not been investigated in patients with severe renal impairment, with dose adjustments currently required because of tolerability concerns [9, 15].”
BackgroundDibenzazepine-linked isoxazoles: New and potent class of α-glucosidase inhibitors
Umm-E-Farwa, Ullah, S., Khan, M. A., Zafar, H., Wahab, A., Younus, M., Choudhary, M. I., & Basha, F. Z. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127979 · Cited by 12
Istrate, D., & Crisan, L. (2023) · Processes · doi:10.3390/pr11113100 · Cited by 8
Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
Tessier, N., Moawad, F., Amri, N., Brambilla, D., & Martel, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081200 · Cited by 9
“Diabetes Exenatide Lixisenatide Liraglutide Exenatide LAR Albiglutide Dulaglutide GLP-1 analogues [117] Exenatide: 5–10 μg twice a day Lixisenatide: 10–20 μg once daily Liraglutide: 0.”
BackgroundChronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges
Lees, J. S., Škoberne, A., Zhang, L., Wyatt, C., Fabian, J., Wang, A. Y.-M., Oni, L., & Levin, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00653-7 · Cited by 6
Winkler, G., Hajós, P., & Kis, J. T. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31615 · Cited by 8
“Egy – állatkísérletes – megfigyelésben a még ZP10A jelű, egyébként rövid hatású (féléletidő 4,3 óra), később lixiszenatidként ismertté vált molekula GLP1-receptorhoz történő kötődését mintegy négyszer erősebbnek találták a humán GLP1-énél [22, 28].”
Meyer, J., Dreischmeier, E., Lehmann, M., & Phelan, J. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221107381 · Cited by 6
“8%) Time since diabetes diagnosis (years)b (n=50) 20 ± 8; (4-42) Weight (kg)b (n=68) 127.”
Immunology and treatments of fatty liver disease
Tang, S., Wu, S., Zhang, W., Ma, L., Zuo, L., & Wang, H. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03920-1 · Cited by 6
“Agonists of the GLP-1 receptor (GLP-1R) or GLP-1 analogs have shown therapeutic efficacy in the treatment of obesity NASH and ALD (Arvanitakis et al. 2022; Ding et al. 2006; Hinnen 2017; Mahalingam et al. 2023; Mantovani et al. 2021; Patel Chavez et al. 2022).”
Blinded by the drug? A vigilyze signal linking semaglutide to NAION
Suresh, J., & Kalaiselvan, V. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03760-7 · Cited by 6
“It plays an important role in regulating blood sugar by enhancing insulin release from pancreatic beta cells but only when blood sugar levels are high [7–9].”
He, S., & Lim, G. E. (2022) · Advanced Biology · doi:10.1002/adbi.202200151 · Cited by 8
Effect of incretins on skeletal health
Starup‐Linde, J., Hygum, K., & Langdahl, B. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000813 · Cited by 6
“The incretins decrease blood glucose and both GIP and GLP-1 analogues are marketed for the treatment of type 2 diabetes showing beneficial effects on glucose homeostasis [6,7].”
BackgroundPeneva, A., Dimitrov, M. V., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e120141 · Cited by 6
Knakker, B., Inkeller, J., Kovács, P., Lendvai, B., & Hernádi, I. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01981-5 · Cited by 6
“Exenatide (Ex), a 39-amino-acid GLP-1 analogue peptide, is a potent agonist with high af fi nity for GLP-1Rs and has a signi fi cantly longer biological half-life than the exogenously administered GLP-1, which makes it an ef fi cient treatment option in noninsulin-dependent diabetes mellitus [14 – 17].”
Plasminogen Activator Inhibitor‐1 in the Pathophysiology of Late Life Depression
Métivier, L., Vivien, D., Goy, R., Agin, V., Bui, É., & Benbrika, S. (2024) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70015 · Cited by 6
“In type 2 diabetes, GLP‐1 action is impaired, leading to reduced insulin secretion, increased insulin resistance, and hyperglycemia with a decrease in GLP‐1 receptor expression [111, 112].”
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Ghanbarnezhad, M. M., Shahsavani, M. B., Mali, P. S., Upadhyay, M., Kumar, A., Albaghlany, R. M., Niazi, A., & Yousefi, R. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130150 · Cited by 6
Paul, A., Das, P. N., & Chatterjee, S. (2022) · Applied Mathematical Modelling · doi:10.1016/j.apm.2022.03.035 · Cited by 9
Protective effects of sitagliptin on methotrexate-induced nephrotoxicity in rats
Fard, L. A., Malekinejad, H., Esmaeilzadeh, Z., Jafari, A., Khezri, M. R., & Ghasemnejad‐Berenji, M. (2023) · Journal of Environmental Science and Health Part C · doi:10.1080/26896583.2023.2186683 · Cited by 8
“This biologic molecule has a short half-life of minutes because of rapid degradation by dipeptidyl peptidase 4 (DPP-4).(15) GLP-1 facilitates glucose-induced insulin release and therefore prevention of its degradation by DPP-4 inhibitor could be a possible approach for the treatment of diabetes.”
BackgroundPharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
Kalinkova, M., Kadiyska, T., & Handjieva‐Darlenska, T. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e104481 · Cited by 6
“The half-life of the autonomic incretins is limited and their effects are decreased in patients with T2D (Holst 2019).”
BackgroundMacIsaac, R. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0210 · Cited by 8
A practical review of diabetes mellitus type 2 treatment in primary care
Call, J. T., Cortés, P., & Harris, D. M. (2021) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2021-0031 · Cited by 7
“Administration of a GLP-1 agonist increases postprandial insulin release, decreases glucagon levels and free fatty acids, slows gastric emptying, and increases satiety [29].”
BackgroundKang, S., Kim, N. H., & Yu, Y. G. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.071 · Cited by 6
Uskoković, V. (2023) · Materials · doi:10.3390/ma16020786 · Cited by 6
“To stabilize the blood glucose levels, diabetics are prescribed insulin or, less commonly, an incretin hormone, such as glucagon-like peptide 1 [17], in one of many forms of delivery.”
MethodBao, T., Xue, C., Wang, Y., Chen, J., Dong, L., Yang, Y., Shi, J., Wang, Z., Tang, R., Wang, X., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145759 · Cited by 5
Translating Metabolic Interventions into Breast Cancer Therapy: A Comprehensive Review
Chen, L., Shiao, S. L., & Yuan, Y. (2025) · Life · doi:10.3390/life15101634 · Cited by 7
“As a result, they are highly efficacious and widely utilized for the management of T2DM [91].”
Liraglutide for adults living with obesity
Meza, N., Bracchiglione, J., Liquitay, C. M. E., Madrid, E., Varela, L. B., Guo, Y., Urrútia, G., er, S. F. S., Tiller, S., Shokraee, K., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016017 · Cited by 16
Bank, N. C., Whittingslow, D. C., Duggan, S., Morningstar, J. L., & Weinberg, D. S. (2025) · World Neurosurgery · doi:10.1016/j.wneu.2025.124751 · Cited by 9
Sosibo, A. M., Mzimela, N. C., Ngubane, P. S., & Khathi, A. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01363-z · Cited by 5
“In T2DM, the incretin hormone levels are dysregulated, resulting in hyperglycaemia [19, 20].”
Comparative risk of infection of medications used for type 2 diabetes
Zapata-Bravo, E., Douros, A., Yu, O. H. Y., & Filion, K. B. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2401024 · Cited by 5
“They are also used as a first-line alternative among patients who cannot tolerate metformin and are recommended when weight loss constitutes a primary treatment objective [84,89].”
Joshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
Kidney consequences of obesity
Nehus, E. J., & Mitsnefes, M. M. (2024) · Pediatric Nephrology · doi:10.1007/s00467-024-06623-y · Cited by 6
“GLP-1 has several metabolically beneficial effects, including improved insulin sensitivity, increasing satiety, decreasing free fatty acid concentrations, and weight loss [66].”
Prudencio, J. B., Cajudoy, P., & Waddell, D. (2021) · Pharmacy · doi:10.3390/pharmacy9040186 · Cited by 6
“GLP-1 agonists cause increased insulin secretion, slowing gastric emptying and suppressing glucagon secretion [9,10].”
BackgroundCoke, L. A., DEEDWANIA, P. C., Hinnen, D., Magwire, M., & Miller, N. H. (2022) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000661 · Cited by 6
Self-citationSafety and Effectiveness of Tirzepatide in Solid-Organ Transplant Recipients
Sweiss, H., Flores, R., Windler, S., Hall, R., Bhayana, S., Patel, R., & Long, C. M. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0071 · Cited by 5
“Two incretin hormones of interest are glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are both produced and released from mucosal cells in the intestinal lining in response to oral glucose intake (2).”
Wang, Q., Jiang, F., Xu, Y., Lei, Y., Zhang, L., & Sun, X. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01569-2 · Cited by 5
“GLP-1RAs are also proposed as a first-line alternative for individuals who are either intolerant to metformin or have contrain-dications to its use [4].”
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Μatsumoto, T., Yagi, T., & Okada, M. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005364 · Cited by 5
Constantine, E. P., Enthoven, L. F., Kahan, R., Pflug, E. M., & Lauder, A. S. (2025) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-24-01505 · Cited by 7
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“Semaglutide, another GLP-1RA, works by up-regulating the down-stream effects of GLP-1 receptor activation [75].”
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Checa-Ros, A., Okojie, O., Wassouf, J. G., Yedean, A., Hsueh, W.-C., Hebda, P., Llobell, E. R., Muhmenthaler, G. B., Tran, M. D.-D., & D’Marco, L. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16020097 · Cited by 6
“…glycemic control, GLP-1RA-induced weight loss, averaging 6.3 kg over 24–52 weeks, confers additional metabolic advantages, including improved lipid profiles, reduced insulin resistance, and decreased hypertension, each of which plays a crucial role in the prevention of diabetic complications [84].”
InfluentialiCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
“Semaglutide, another GLP-1RA, works by upregulating the downstream effects of GLP-1 receptor activation [75].”
Morse, B. L., Coutant, D. E., Ma, X., Raha, S., Aithal, K., Nicoll, C., Rougée, L. R. A., & Bhattachar, S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70377 · Cited by 4
“31,32 With the intention of sorting out effects on enzymes/transporters vs. GLP-1 RA class gastric emptying delay (GED) effect in orforglipron as a precipitant studies, acetaminophen was assessed following a single dose and at 24 and 36 mg capsule daily dosing to steady state of orforglipron.”
Saiti, A., Giannopoulos‐Dimitriou, A., Kazakos, I., Galatou, E., & Vizirianakis, I. S. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010021 · Cited by 5
Escobar, J., Monday, O., Vemoori, Y., Yadav, I., Maslamani, A. N. J., Kutabi, S. A., Saeed, L., & Khan, A. (2023) · Cureus · doi:10.7759/cureus.45927 · Cited by 5
Mayyas, F., & Omeish, A. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123721 · Cited by 5
Tang, C. C., Lim, J. K., Loo, L. S., Jung, H., Кониг, М., & Tham, L. S. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2373 · Cited by 4
Tiwari, R. K., Ahmad, A., Chadha, M., Saha, K., Verma, H., Borgohain, K., & Shukla, R. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998294919240506044544 · Cited by 5
Effects of antidiabetic medications on cardiovascular outcomes
Leung, M. S. T., Lin, S. G., Uthayanan, L., & Harky, A. (2020) · Journal of Cardiac Surgery · doi:10.1111/jocs.14709 · Cited by 4
“The incretin system consists of two incretin hormones glucagon‐ dependent insulinotropic polypeptide and GLP‐1.13 Intravenous administration of GLP‐1 agonists to patients with T2DM activates GLP‐1 receptors and therefore (Figure 3)2: • Lowers glucose levels.”
BackgroundInfluentialTotal synthesis and absolute structure of N55, a positive modulator of GLP-1 signaling
Lin, N.-P., & Chein, R. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob01722a · Cited by 4
Conventional and Alternative Mesenchymal Stem Cell Therapies for the Treatment of Diabetes
Rifai, L., & Saleh, F. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_614 · Cited by 6
Alvarado, C. S., Yang, K., Qiu, H., Mills, E., Fouhse, J. M., Ju, T., Buteau, J., Field, C. J., Willing, B. P., & Chan, C. B. (2021) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00090.2021 · Cited by 4
Park, B. G., Kim, G. M., Lee, H., Ryu, J. H., Kim, D., Seong, J. Y., Kim, S., Park, Z., Kim, Y., Lee, J., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14546 · Cited by 4
“Among the currently available antiobesity medications, the glucagon-like peptide-1 (GLP-1) analogues, which were originally developed as antidiabetic medications, induce weight loss mainly by reducing food intake.(5,6) GLP-1 receptor (GLP-1R) is highly expressed in insulin-producing pancreatic beta cells, and its acti…”
BackgroundFerri, G., Tesi, M., Pesce, L., Bugliani, M., Grano, F., Occhipinti, M., Suleiman, M., Luca, C. D., Marselli, L., Marchetti, P., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091403 · Cited by 5
“Among the several pharmacological treatments for the therapy of diabetes, GLP-1 receptor (GLP-1R) agonists are being used, with a favorable benefit/risk ratio [6,7].”
MethodWard, J., Lyall, L. M., Strawbridge, R. J., Stanciu, I., Veldsman, M., Garfield, V., Celis-Morales, C. A., Newby, D., Stewart, W. B., Jr., Pell, J. P., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14879 · Cited by 4
Lyu, J., Imachi, H., Fukunaga, K., Sato, S., Kobayashi, T., Saheki, T., Japar, S., Iwama, H., Matsumura, Y., Ozaki, M., et al. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44110370 · Cited by 4
“Glucagon-like peptide-1 receptor agonists (GLP-1 RA) were originally approved for the treatment of type 2 diabetes by enhancement of glucose-stimulated insulin secretion [4].”
BackgroundHarris, S. B., Mohammedi, K., Bertolini, M., Carlyle, M. H., Walker, V., Zhou, F. L., Anderson, J. E., & Seufert, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15240 · Cited by 4
Praveen Kumar Reddy, J., Tummuru, M. K. R., & Ramkumar, K. M. (2024) · Process Biochemistry · doi:10.1016/j.procbio.2024.09.001 · Cited by 3
Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?
Lang, K. (2025) · BMJ · doi:10.1136/bmj.q2636 · Cited by 4
Semaglutide and the skin: A brief review of dermatologic implications
Salam, A., & Hyder, M. S. (2025) · Cosmoderma · doi:10.25259/csdm_97_2025 · Cited by 3
Mazzei, K., Trippett, A. N., Hedrick, T. D., & Wen, S. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.06.023 · Cited by 3
Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?
Bellary, S., Tahrani, A. A., & Barnett, A. H. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30301-6 · Cited by 3
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
“Nausea (25–60%) followed by vomiting (5–15%) and diarrhoea (10–20%) are the most frequently reported treatment‐related adverse effects occurring with GLP‐1 RAs in previous clinical trials.[89]”
BackgroundIntegrating semaglutide into obesity management – a primary care perspective
Kyrillos, J. V., SKOLNIK, N., Mukhopadhyay, B., & Pennings, N. J. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2149964 · Cited by 4
Diabetes and diabesity in the view of proteomics, drug, and plant-derived remedies
Haeri, M. R. (2023) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_487_22 · Cited by 4
“[128] GLP‑1 receptor agonists increase insulin sensitivity, suppress appetite, decrease glucagon, HbA1C, and free fatty acid levels and decrease body weight.”
BackgroundGlucagon-like Peptide-1 Receptor Agonists: Limitless Potential
Demidova, T. Y., & Kozhevnikov, A. A. (2020) · Doctor Ru · doi:10.31550/1727-2378-2020-19-2-6-12 · Cited by 3
“За счет ингибирования моторики желудка и подавления аппетита они способствуют снижению веса [22].”
Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy
Butler, J., Bjurstrom, M., & Marceau, A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab045 · Cited by 3
Back, H.-M., Choi, S.-A., & Kim, M. G. (2023) · Drug Targets and Therapeutics · doi:10.58502/dtt.23.0003 · Cited by 3
Dissecting the Interrelationship between COVID‐19 and Diabetes Mellitus
Roham, P. H., Kamath, J., & Sharma, S. (2023) · Advanced Biology · doi:10.1002/adbi.202300107 · Cited by 4
Shin, W., Hompesch, M., Byeon, J., Kang, S., Choi, J., & Baek, S. J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15162 · Cited by 3
Conroy, L., McCann, A., Zhang, N., & de Gaetano, M. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00695.2023 · Cited by 5
Alghamdi, F. A., Alshegifi, H., Alhuthayli, R., Helal, T., Huwait, T. A., Alharbi, T., Akbar, A. F., Alshehri, W., & Alsheikh, S. (2024) · Cureus · doi:10.7759/cureus.74345 · Cited by 3
Anti-diabetic Biologicals: Exploring the Role of Different Analytical Techniques
Yaseen, Z., Nandave, M., & Sharma, L. K. (2025) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2025.2472793 · Cited by 3
Choxi, R., Roy, S., Stamatouli, A. M., Mayer, S., & Jovin, I. S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1756778 · Cited by 3
“suppressing appetite, and slowing gastric emptying [56].”
Pharmacotherapy of Type 2 Diabetes
Kaur, J., Famta, P., Khurana, N., Vyas, M., & Khatik, G. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_50 · Cited by 3
Ismail, R. (2020) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.10468 · Cited by 5
Type 2 diabetes and the role of nurses in its management
Butler, S. M. (2025) · Nursing Standard · doi:10.7748/ns.2025.e12429 · Cited by 4
What Clinicians Need to Know About Glucagon-like Peptide 1 Agonists
da Silva, D. L. F., Singla, S., & Mease, P. J. (2025) · The Journal of Rheumatology · doi:10.3899/jrheum.2025-0531 · Cited by 3
Hyperglycemia in the focus of prevention of age-related skin changes
Shperling, N. V., Chaplygin, A. V., & Васильевна, Ч. Н. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-360 · Cited by 2
Benavidez, M. C., Redpath, S., Trautmann, S., Ceron, S. A., Schimpke, S. W., Myers, J. A., Omotosho, P. A., Torquati, A., & Skertich, N. J. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.09.010 · Cited by 2
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
“…blood glucose by (1) promoting glucose-dependent insulin secretion and suppressing glucagon, thus reducing hypoglycemia risk; (2) slowing gastric emptying to mitigate post-prandial glucose spikes; and (3) suppressing appetite via central nervous system effects, leading to weight loss (38, 39).”
Sciscent, B. Y., Eberly, H. W., Lorenz, F. J., Goldrich, D. Y., Goyal, N., & Goldenberg, D. (2026) · OTO Open · doi:10.1002/oto2.70188 · Cited by 2
GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications
Mejia, M. R., Tiao, J., Yu, A., Baidya, J., Rajjoub, M., Torres, R. B., & Chaudhary, S. B. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261438492 · Cited by 2
Metadata
- Authors
- Hinnen, D.
- Affiliations
- University of Colorado Health (US)
- Corresponding author
- Hinnen, Deborah
- ORCID
- Hinnen, Deborah
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2017-08-01
- Volume
- 30
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC5556578
- OpenAlex
- W2592545469
- Cited by
- 394
- References
- 53
- Citations by year
- 2026: 23 · 2025: 71 · 2024: 59 · 2023: 57 · 2022: 53 · 2021: 59 · 2020: 46 · 2019: 22 · 2018: 3 · 2017: 1
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- AstraZeneca
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, incretin system, exenatide, liraglutide, lixisenatide, exenatide extended-release, albiglutide, dulaglutide, glycemic control, weight loss, hypoglycemia risk, gastrointestinal adverse effects, patient selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.